10-Sep-2018 | Zion Market Research
Zion Market Research has published a new report titled “Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”. According to the report, global scleroderma diagnostics and therapeutics market was valued at approximately USD 1,607.27 million in 2017 and is expected to generate revenue of around USD 3,165.85 million by end of 2024, growing at a CAGR of around 10.21% between 2018 and 2024.
Scleroderma is an autoimmune condition that is characterized by hard and thickened skin along with blood vessel problems. Scleroderma is a connective tissue disease that results in an overactive immune system. This condition can also lead to scarring, pain, and inflammation. Scleroderma, a chronic disease, sometimes leads to scarring on kidneys and lungs. It might cause blood vessels to thicken leading to high blood pressure and tissue damage. This condition is not infectious, cancerous, or contagious. Scleroderma symptoms vary from person to person.
Browse the full "Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024" report at https://www.zionmarketresearch.com/report/scleroderma-diagnostics-and-therapeutics-market
There are two types of scleroderma: localized and systemic. In localized scleroderma, the condition is limited to the skin and internal organs are not affected. Apart from the skin, localized scleroderma may also affect underlying muscle and tissue. In systemic scleroderma, the condition spreads to visceral organs. The vascular and the immune systems are affected by systemic scleroderma. Blood vessels are also affected leading to spasmodic color changes. This condition is referred to as Raynaud phenomenon.
The diagnosis of scleroderma is very difficult as it resembles a variety of other disorders. The diagnosis of scleroderma is done by a dermatologist, respirologist, orthopaedist, rheumatologist, or a general internist. The diagnosis relies majorly on the physical examination along with a study of medical history. The diagnosis process starts with a discussion with the patient to note down the medical history followed by a physical examination that includes observation of the affected areas. In order to confirm the diagnosis, the doctor might suggest lab tests. The doctor might also suggest for a skin biopsy. If the affected person shows typical symptoms and skin thickening the diagnosis becomes very easy. However, in some cases, the diagnosis takes several months.
The treatment for scleroderma is aimed at the individual features that influence different areas of the body. To prevent kidney failure, elevated blood pressure levels are treated. Angiotensin-converting enzyme (ACE) inhibitor class of drugs are frequently used to alleviate blood pressure. There is no medicine available to stop the overproduction of collagen. However, the symptoms and complications of scleroderma can be abated by using multiple medicines. Immunosuppressant drugs are used to reduce the symptoms of scleroderma. Various ointments are also used to prevent infection. Physicians also prescribe mild to strong painkillers. Surgical procedures are used as last resort that includes amputation and lung transplants.
Around 300,000 people have scleroderma in the United States. Out of these, one-third people have systemic scleroderma. As scleroderma develops progressively and appears in varied forms, it is not very easy to diagnose. Currently, a cure for scleroderma doesn’t exist as overproduction of collagen cannot be stopped by any medication. It is, however, possible to treat organ system complications for minimizing damage and maintaining functionality.
Rising incidence of scleroderma and increasing frequency of genetic mutations along with severe environmental changes are the major drivers that will boost the growth of scleroderma diagnostics and therapeutics market. Moreover, the rise in disposable income and increasing awareness regarding preventive healthcare is expected to take the market to new heights. Factors such as extensive R&D related to diagnosis and treatment of scleroderma will create opportunities for the market players. Unfavorable drug effects, ironclad government regulations, high costs related to the diagnosis of scleroderma are some of the factors that will restrict the growth of scleroderma diagnostics and therapeutics market.
The global scleroderma diagnostics and therapeutics market have been segmented into drug class, indication, diagnostic test type, and region. The drug class segment has been segmented into immunosuppressive agents, corticosteroids, endothelin receptor agonists, calcium channel blockers, chelating agents, PDE-5 inhibitors, H2 blockers, prostacyclin analogs, ACE inhibitors, and proton pump inhibitors. Based on the indication, scleroderma diagnostics and therapeutics market have been segmented into systemic and localized. Based on diagnostic test type, scleroderma diagnostics and therapeutics market have been segmented into imaging techniques, skin biopsy, electrocardiogram and echocardiogram, pulmonary function tests, and blood test.
North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America are key regional segments of global scleroderma diagnostics and therapeutics market. North America is anticipated to remain the leading region over the forecast period followed by Europe. Demand for scleroderma diagnostics and therapeutics market products was highest in North America especially in the U.S. Asia Pacific is expected to be the highest growing region in scleroderma diagnostics and therapeutics market during the forecast period. Moreover, the Middle East & Africa and Latin America are also expected to show moderate growth for this market in the years to come.
Some of the key players in the scleroderma diagnostics and therapeutics market include Bayer AG, Allergan, Inc., Active Biotech AB, BioLineRx, Ltd., Digna Biotech, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Vida Therapeutics Inc., Angion Biomedica Corp., Daval International Ltd., Corbus Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd., among others.
This report segments the global scleroderma diagnostics and therapeutics market as follows:
Global Scleroderma Diagnostics and Therapeutics Market: By Drug Class
Global Scleroderma Diagnostics and Therapeutics Market: By Indication
Global Scleroderma Diagnostics and Therapeutics Market: By Diagnostic Test Type
Global Scleroderma Diagnostics and Therapeutics Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed